

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/264535633>

# Synthesis, antimicrobial and anticancer activities of amido sulfonamido methane linked bis heterocycles

ARTICLE *in* ARABIAN JOURNAL OF CHEMISTRY · SEPTEMBER 2014

Impact Factor: 3.73 · DOI: 10.1016/j.arabjc.2013.10.024

---

CITATION

1

---

READS

28

7 AUTHORS, INCLUDING:



Tack-Joong Kim

Yonsei University


95 PUBLICATIONS 1,077 CITATIONS

SEE PROFILE



King Saud University  
Arabian Journal of Chemistry

www.ksu.edu.sa  
www.sciencedirect.com



REVIEW

2nd Cancer Update

# Synthesis, antimicrobial and anticancer activities of amido sulfonamido methane linked bis heterocycles



Chokkappagari Premakumari <sup>a</sup>, Akkarapalli Muralikrishna <sup>a</sup>,  
Adivireddy Padmaja <sup>a</sup>, Venkatapuram Padmavathi <sup>a,\*</sup>, Sea Jin Park <sup>b</sup>,  
Tack-Joong Kim <sup>b</sup>, Guda Dinneswara Reddy <sup>c</sup>

<sup>a</sup> Department of Chemistry, Sri Venkateswara University, Tirupati 517 502, Andhra Pradesh, India

<sup>b</sup> Division of Biological Science & Technology, College of Science and Technology, Yonsei University, Wonju 220-710, South Korea

<sup>c</sup> Department of Chemistry & Medicinal Chemistry, College of Science and Technology, Yonsei University, Wonju 220-710, South Korea

Received 4 October 2012; accepted 21 October 2013

Available online 28 October 2013

## KEYWORDS

Oxazoles;  
Thiazoles;  
Imidazoles;  
Antimicrobial activity;  
Anticancer activity

**Abstract** A new class of amido sulfonamido methane linked bis heterocycles- bis-oxazoles, thiazoles and imidazoles were prepared and screened for antimicrobial and anticancer activities. The chloro substituted amido sulfonamido bisimidazole exhibited excellent antimicrobial activity and also it was the most potent compound on lung, colon and prostate cancer cell lines.

© 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.


## Contents

|  |     |
|--|-----|
| 1. Introduction . . . . .  | 386 |
| 2. Experimental. . . . .   | 386 |
| 2.1. General . . . . .   | 386 |
| 2.2. Synthesis of bis(carbethoxymethylsulfonyl)amine (2) . . . . . | 386 |
| 2.3. Synthesis of bis(carboxymethylsulfonyl)amine (3). . . . .     | 387 |

\* Corresponding author. Tel.: +91 877 2249666x303; fax: +91 877 2248499.

E-mail address: [vkpuram2001@yahoo.com](mailto:vkpuram2001@yahoo.com) (V. Padmavathi).

Peer review under responsibility of King Saud University.



|   |     |
|---|-----|
| 2.4. General procedure for the synthesis of bis(N-(4-aryloxazol-2-yl)aminocarbonyl-methylsulfonyl)amine (7a-c)/bis(N-(4-arylthiazol-2-yl)aminocarbonyl-methylsulfonyl)amine (8a-c)/bis(N-(4-aryl-1H-imidazol-2-yl)aminocarbonyl-methylsulfonyl)amine (9a-c) . . . . . | 387 |
| 2.4.1. Bis(N-(4-phenyloxazol-2-yl) aminocarbonylmethylsulfonyl)amine (7a) . . . . .   | 387 |
| 2.4.2. Bis(N-(4-p-tolyloxazol-2-yl) aminocarbonylmethylsulfonyl)amine (7b) . . . . .  | 387 |
| 2.4.3. Bis(N-(4-p-chlorophenyloxazol-2-yl) aminocarbonylmethylsulfonyl)amine (7c) . . . . .   | 387 |
| 2.4.4. Bis(N-(4-phenylthiazol-2-yl) aminocarbonylmethylsulfonyl)amine (8a) . . . . .  | 387 |
| 2.4.5. Bis(N-(4-p-tolylthiazol-2-yl) aminocarbonylmethylsulfonyl)amine (8b) . . . . .   | 387 |
| 2.4.6. Bis(N-(4-p-chlorophenylthiazol-2-yl) aminocarbonylmethylsulfonyl)amine (8c) . . . . .  | 387 |
| 2.4.7. Bis(N-(4-phenyl-1H-imidazol-2-yl) aminocarbonylmethylsulfonyl)amine (9a) . . . . .   | 388 |
| 2.4.8. Bis(N-(4-p-tolyl-1H-imidazol-2-yl) aminocarbonylmethylsulfonyl)amine (9b) . . . . .  | 388 |
| 2.4.9. Bis(N-(4-p-chlorophenyl-1H-imidazol-2-yl) aminocarbonylmethylsulfonyl)amine (9c) . . . . .   | 388 |
| 2.5. Antimicrobial activity . . . . .   | 388 |
| 2.5.1. Microbial cultures . . . . .   | 388 |
| 2.5.2. Antibacterial and antifungal assays . . . . .  | 388 |
| 2.5.3. Minimum inhibitory concentration assay . . . . .   | 388 |
| 2.5.4. Minimum bactericidal/fungicidal concentration . . . . .  | 389 |
| 2.6. Anticancer assays . . . . .  | 390 |
| 2.6.1. Compounds . . . . .  | 390 |
| 2.6.2. Cell cultures . . . . .  | 390 |
| 2.6.3. Measurement of cancer cell viability . . . . .   | 390 |
| 2.6.4. Statistical analysis . . . . .   | 390 |
| 3. Results and discussion . . . . .   | 390 |
| 3.1. Chemistry . . . . .  | 390 |
| 3.2. In-vitro antimicrobial activity . . . . .  | 392 |
| 3.3. In-vitro anticancer activity . . . . .   | 392 |
| 4. Conclusion . . . . .   | 394 |
| Acknowledgements . . . . .  | 394 |
| References . . . . .  | 394 |

## 1. Introduction

Sulfonamide drugs are associated with a wide range of biological activities and in fact brought an antibiotic revolution in medicine (Ali et al., 2006; McCarroll et al., 2007; Wilkinson et al., 2007). Many oxazole and/or thiazole containing macrocycles are naturally occurring molecules, viz., Bistratamides (You and Kelly, 2005), Didmolamides A and B (You and Kelly, 2005), Lyngbyabellin A (Yokokawa et al., 2001), and Calyculins (Yokokawa et al., 2001; Degnan et al., 1989; Pihko and Koskinen, 1998; Perez and Faulkner, 2003; Rudi et al., 2003; Tan et al., 2003), which show cytotoxic, antimicrobial and multiple drug resistance activities. Several classes of drugs based on imidazole viz., 2-nitroimidazole commonly called Azomycin are a natural antibiotic. Some synthetic nitroimidazoles are active against intestinal infections (Breccia et al., 1986). In fact metronidazole is used for intestinal infections and also as a radiosensitizer in X-ray therapy (Middlemiss and Watson, 1994). The incorporation of sulfonamide moiety into heterocyclic rings can produce pharmacologically potent compounds. The present work comprises design and synthesis of new molecules having two pharmacophoric heterocyclic units linked by bis methane amido sulfonamido moiety which are expected to have pharmacological activity. Although chemically unrelated to these compounds, other classes of antibiotics such as the anthracyclines (Miller and Stoodley, 2011) which were originally isolated from strains of *Streptomyces peucetius*, show antibacterial activity (mostly against Gram positive bacteria, for example *Staphylococcus aureus*) and have been in clinical use for the treatment of various forms of cancer

for several decades. Triazolopyrazole thiones also exhibit antibacterial, antifungal and promising anticancer activities; the latter compared with the anthracycline doxorubicin.

## 2. Experimental

### 2.1. General

Melting points were determined in open capillaries on a Mel-Temp apparatus and are uncorrected. The purity of the compounds was checked by TLC (silica gel H, BDH, ethyl acetate/hexane, 1:3). The IR spectra were recorded on a Thermo Nicolet IR 200 FT-IR spectrometer as KBr pellets and the wavenumbers were given in  $\text{cm}^{-1}$ . The  $^1\text{H}$  NMR spectra were recorded in  $\text{DMSO}-d_6$  on a Bruker spectropin operating at 400 MHz. The  $^{13}\text{C}$  NMR spectra were recorded in  $\text{DMSO}-d_6$  on Bruker spectropin operating at 100 MHz. All chemical shifts are reported in  $\delta$  (ppm) using TMS as an internal standard. The microanalyses were performed on a Perkin-Elmer 240C elemental analyzer. For anticancer activity the optical density was determined at 450 nm using a microplate reader (BioTek Instruments Inc., Winooski, VT, USA).

### 2.2. Synthesis of bis(carbethoxymethylsulfonyl)amine (2)

To a solution of ethyl sulfamylacetate (1) (0.003 mol) in dichloromethane (10 ml), triethylamine (0.0031 mol), and 4-dimethylaminopyridine (DMAP) (0.0001 mol) were added and stirred at room temperature for 15 min. Then, a solution of ethyl 2-chlorosulfonylacetate (0.0033 mol) in dichlorometh-

ane (5 ml) was added dropwise and the reaction mixture was stirred at 40 °C under nitrogen atmosphere for 6–10 h. After completion of reaction the solvent was removed *in vacuo*. The resultant residue was neutralized with saturated NaHCO<sub>3</sub> solution and the aqueous layer was extracted with ethyl acetate (3 × 15 ml), washed with water (3 × 20 ml), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under vacuum and the residual solid was purified by column chromatography (silica gel, 60–120 mesh) using hexane-ethyl acetate (3:1) as eluent.

Yield 72%, m.p. 132–134 °C. IR (KBr):  $\nu$  = 3370 (NH), 1730 (C=O), 1320, 1136 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS):  $\delta$  = 1.36 (t, 6H, CH<sub>3</sub>), 4.20 (q, 4H, OCH<sub>2</sub>), 4.42 (s, 4H, CH<sub>2</sub>), 8.01 (bs, 1H, NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 14.2 (CH<sub>3</sub>), 55.8 (CH<sub>2</sub>), 61.4 (OCH<sub>2</sub>), 161.5 (C=O) ppm. Anal. For C<sub>8</sub>H<sub>15</sub>NO<sub>8</sub>S<sub>2</sub> (317.35) calcd. C30.27, H4.76, N 4.41. Found C30.32, H4.74, N4.47.

### 2.3. Synthesis of bis(carboxymethylsulfonfyl)amine (3)

A mixture of bis(carbethoxymethylsulfonfyl)amine (2) (0.0025 mol), KOH (0.01 mol) in methanol (10 ml) and water (25 ml) was refluxed for 2–3 h. To this charcoal was added, boiled for 5 min. and filtered through celite. The filtrate was acidified with dil. HCl and extracted with ether. Removal of the solvent on a rotary evaporator resulted in compound 3.

Yield 80%, m.p. 145–147 °C. IR (KBr):  $\nu$  = 3372 (NH), 3355 (OH), 1716 (C=O), 1323, 1141 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS):  $\delta$  = 4.54 (s, 4H, CH<sub>2</sub>), 7.96 (bs, 1H, NH), 10.43 (bs, 2H, OH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 57.6 (CH<sub>2</sub>), 174.2 (C=O) ppm. Anal. calcd For C<sub>4</sub>H<sub>7</sub>NO<sub>8</sub>S<sub>2</sub> (261.24) calcd. C18.39, H2.70, N5.36. Found: C18.46, H2.71, N5.44.

### 2.4. General procedure for the synthesis of bis(*N*-(4-aryloxazol-2-yl)aminocarbonyl-methylsulfonfyl)amine (7a-c)/bis(*N*-(4-arylthiazol-2-yl)aminocarbonyl-methylsulfonfyl)amine (8a-c)/bis(*N*-(4-aryl-1H-imidazol-2-yl)aminocarbonyl-methylsulfonfyl)amine (9a-c)

To a solution of compound 3 (0.001 mol) in dioxane (20 ml), compound 4/5/6 (0.002 mol) and 4-dimethylaminopyridine (DMAP) (0.0001 mol) were added. Then dicyclohexylcarbodiimide (DCC) (0.0014 mol) in dioxane (10 ml) was added dropwise to the contents while stirring at room temperature and continued the stirring for another 20–24 h. The separated precipitate, a dicyclohexylurea was removed by filtration. The solution was evaporated to dryness and the residual solid was purified by column chromatography (silica gel, 60–120 mesh) using hexane-ethyl acetate (3:1) as eluent.

#### 2.4.1. Bis(*N*-(4-phenyloxazol-2-yl)aminocarbonylmethylsulfonfyl)amine (7a)

Yield 65%, m.p. 186–187 °C. IR (KBr):  $\nu$  = 3344 (NH), 1690 (C=O), 1634 (C=C), 1574 (C=N), 1326, 1138 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 4.52 (s, 4H, CH<sub>2</sub>), 7.44–7.88 (m, 12H, Ar-*H* and C<sub>5</sub>-*H*), 8.03 (bs, 1H, SO<sub>2</sub>NH), 8.46 (bs, 2H, CO-NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 56.2 (CH<sub>2</sub>), 128.9,

129.1, 130.0, 132.6 (Ar-C), 138.2 (C-5), 140.3 (C-4), 149.7 (C-2), 167.2 (C=O) ppm. Anal. calcd For C<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O<sub>8</sub>S<sub>2</sub> (545.55) calcd. C48.43, H3.51, N12.83. Found: C48.39, H3.54, N12.93.

#### 2.4.2. Bis(*N*-(4-*p*-tolylloxazol-2-yl)aminocarbonylmethylsulfonfyl)amine (7b)

Yield 67%, m.p. 172–174 °C. IR (KBr):  $\nu$  = 3338 (NH), 1683 (C=O), 1630 (C=C), 1580 (C=N), 1324, 1135 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 2.40 (s, 6H, Ar-CH<sub>3</sub>), 4.48 (s, 4H, CH<sub>2</sub>), 7.15–7.48 (m, 10H, Ar-*H* and C<sub>5</sub>-*H*), 8.05 (bs, 1H, SO<sub>2</sub>NH), 8.43 (bs, 2H, CO-NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 24.8 (Ar-CH<sub>3</sub>), 56.0 (CH<sub>2</sub>), 127.3, 129.4, 131.0, 137.2 (Ar-C), 137.8 (C-5), 139.5 (C-4), 148.4 (C-2), 167.2 (C=O) ppm. Anal. For C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>8</sub>S<sub>2</sub> (573.60) calcd. C50.25, H, 4.04, N12.20. Found: C50.30, H4.03, N12.29.

#### 2.4.3. Bis(*N*-(4-*p*-chlorophenylloxazol-2-yl)aminocarbonylmethylsulfonfyl)amine (7c)

Yield 70%, mp 201–202 °C. IR (KBr):  $\nu$  = 3350 (NH), 1694 (C=O), 1627 (C=C), 1568 (C=N), 1332, 1145 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 4.45 (s, 4H, CH<sub>2</sub>), 7.37–7.66 (m, 10H, Ar-*H* and C<sub>5</sub>-*H*), 7.98 (bs, 1H, SO<sub>2</sub>NH), 8.48 (bs, 2H, CO-NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 56.5 (CH<sub>2</sub>), 127.5, 129.1, 132.4, 135.8 (Ar-C), 138.5 (C-5), 140.8 (C-4), 150.2 (C-2), 167.9 (C=O) ppm. Anal. For C<sub>22</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>8</sub>S<sub>2</sub> (614.44) calcd. C43.00, H2.78, N11.40. Found: C43.07, H2.80, N11.48.

#### 2.4.4. Bis(*N*-(4-phenylthiazol-2-yl)aminocarbonylmethylsulfonfyl)amine (8a)


Yield 72%, m.p. 190–192 °C. IR (KBr):  $\nu$  = 3355 (NH), 1685 (C=O), 1632 (C=C), 1570 (C=N), 1322, 1140 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 4.45 (s, 4H, CH<sub>2</sub>), 7.20–7.56 (m, 12H, Ar-*H* and C<sub>5</sub>-*H*), 7.94 (bs, 1H, SO<sub>2</sub>NH), 8.42 (bs, 2H, CO-NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 55.9 (CH<sub>2</sub>), 103.7 (C-5), 126.7, 127.6, 128.8, 132.0 (Ar-C), 148.0 (C-4), 162.8 (C-2), 167.4 (C=O) ppm. Anal. For C<sub>22</sub>H<sub>19</sub>N<sub>5</sub>O<sub>6</sub>S<sub>4</sub> (577.68) calcd. C45.74, H3.31, N12.12. Found: C45.79, H3.30, N12.03.

#### 2.4.5. Bis(*N*-(4-*p*-tolylthiazol-2-yl)aminocarbonylmethylsulfonfyl)amine (8b)

Yield 69%, m.p. 183–185 °C. IR (KBr):  $\nu$  = 3348 (NH), 1673 (C=O), 1641 (C=C), 1565 (C=N), 1326, 1137 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 2.38 (s, 6H, Ar-CH<sub>3</sub>), 4.43 (s, 4H, CH<sub>2</sub>), 7.10–7.43 (m, 10H, Ar-*H* and C<sub>5</sub>-*H*), 8.01 (bs, 1H, SO<sub>2</sub>NH), 8.39 (bs, 2H, CO-NH) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 24.5 (Ar-CH<sub>3</sub>), 55.3 (CH<sub>2</sub>), 103.0 (C-5), 127.9, 129.5, 130.6, 136.8 (Ar-C), 147.7 (C-4), 162.1 (C-2), 166.6 (C=O) ppm. Anal. For C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>6</sub>S<sub>4</sub> (605.73) calcd. C47.58, H3.82, N11.56. Found: C47.54, H3.85, N11.66.

#### 2.4.6. Bis(*N*-(4-*p*-chlorophenylthiazol-2-yl)aminocarbonylmethylsulfonfyl)amine (8c)

Yield 75%, m.p. 215–217 °C. IR (KBr):  $\nu$  = 3368 (NH), 1687 (C=O), 1631 (C=C), 1575 (C=N), 1328, 1143 (SO<sub>2</sub>) cm<sup>-1</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>, 25 °C, TMS)  $\delta$  = 4.38 (s,



**Scheme 1** Synthesis of amido sulfonamido methane linked bis heterocycles.

4H,  $CH_2$ ), 7.26–7.60 (m, 10H, Ar-*H* and  $C_5$ -*H*), 8.02 (bs, 1H,  $SO_2NH$ ), 8.50 (bs, 2H, CO-*NH*) ppm;  $^{13}C$  NMR (100 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 56.2 ( $CH_2$ ), 104.2 ( $C_5$ ), 127.8, 129.0, 131.4, 135.0 (Ar-*C*), 148.4 ( $C_4$ ), 163.2 ( $C_2$ ), 167.8 ( $C=O$ ), Anal. For  $C_{22}H_{17}Cl_2N_5O_6S_4$  (646.57) calcd. C40.86, H2.65, N10.83. Found: C40.90, H2.63, N10.90.

**2.4.7. Bis(*N*-(4-phenyl-1*H*-imidazol-2-yl)aminocarbonylmethylsulfonyl)amine (9a)**

Yield 77%, m.p. 224–226 °C. IR (KBr):  $\nu$  = 3372 (NH), 1665 ( $C=O$ ), 1643 ( $C=C$ ), 1560 ( $C=N$ ), 1330, 1140 ( $SO_2$ )  $cm^{-1}$ .  $^1H$  NMR (400 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 4.40 (s, 4H,  $CH_2$ ), 7.15–7.50 (m, 12H, Ar-*H* and  $C_5$ -*H*), 8.04 (bs, 1H,  $SO_2NH$ ), 8.38 (bs, 2H, CO-*NH*), 11.35 (bs, 2H, *NH*) ppm;  $^{13}C$  NMR (100 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 55.0 ( $CH_2$ ), 120.3 ( $C_5$ ), 127.4, 128.2, 129.7, 132.0 (Ar-*C*), 137.5 ( $C_2$ ), 140.0 ( $C_4$ ), 166.4 ( $C=O$ ) ppm. Anal. For  $C_{22}H_{21}N_7O_6S_2$  (543.59) calcd. C48.61, H3.89, N18.03. Found: C48.68, H3.90, N18.14.

**2.4.8. Bis(*N*-(4-*p*-tolyl-1*H*-imidazol-2-yl)aminocarbonylmethylsulfonyl)amine (9b)**

Yield 74%, m.p. 198–200 °C. IR (KBr):  $\nu$  = 3370 (NH), 1660 ( $C=O$ ), 1638 ( $C=C$ ), 1550 ( $C=N$ ), 1325, 1130 ( $SO_2$ )  $cm^{-1}$ .  $^1H$  NMR (400 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 2.36 (s, 6H, Ar- $CH_3$ ), 4.38 (s, 4H,  $CH_2$ ), 7.09–7.40 (m, 10H, Ar-*H* and  $C_5$ -*H*), 7.96 (bs, 1H,  $SO_2NH$ ), 8.35 (bs, 2H, CO-*NH*), 11.28 (bs, 2H, *NH*) ppm;  $^{13}C$  NMR (100 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 24.7 (Ar- $CH_3$ ), 54.7 ( $CH_2$ ), 120.1 ( $C_5$ ), 127.7, 129.6, 130.8, 135.4 (Ar-*C*), 137.1 ( $C_2$ ), 139.7 ( $C_4$ ), 166.0 ( $C=O$ ) ppm. Anal. For  $C_{24}H_{25}N_7O_6S_2$  (571.64) calcd. C50.42, H4.40, N17.15. Found: C50.49, H4.44, N17.24.

**2.4.9. Bis(*N*-(4-*p*-chlorophenyl-1*H*-imidazol-2-yl)aminocarbonylmethylsulfonyl)amine (9c)**

Yield 78%, m.p. 243–245 °C. IR (KBr):  $\nu$  = 3375 (NH), 1673 ( $C=O$ ), 1640 ( $C=C$ ), 1562 ( $C=N$ ), 1335, 1144 ( $SO_2$ ).  $^1H$  NMR (400 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 4.42 (s, 4H,  $CH_2$ ), 7.20–7.55 (m, 10H, Ar-*H* and  $C_5$ -*H*), 7.99 (bs, 1H,  $SO_2NH$ ), 8.40 (bs, 2H, CO-*NH*), 11.40 (bs, 2H, *NH*) ppm;  $^{13}C$  NMR (100 MHz,  $DMSO-d_6$ , 25 °C, TMS)  $\delta$  = 55.8 ( $CH_2$ ), 120.7 ( $C_5$ ), 128.9, 130.1, 130.9, 135.5 (Ar-*C*), 137.9

( $C_2$ ), 140.4 ( $C_4$ ), 166.8 ( $C=O$ ) ppm. Anal. For  $C_{22}H_{19}Cl_2N_7O_6S_2$  (612.48) calcd. C43.14, H3.12, N16.00. Found: C43.20, H3.11, N16.08.

**2.5. Antimicrobial activity**

The compounds **3–9** were evaluated for antimicrobial activity by the agar well diffusion method and broth dilution methods.

**2.5.1. Microbial cultures**

Bacterial strains *S. aureus*, *Bacillus subtilis*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae* and fungi *Aspergillus niger* and *Penicillium chrysogenum* were obtained from the Department of Microbiology, S.V University, Tirupati, India.

**2.5.2. Antibacterial and antifungal assays**

The *in vitro* antimicrobial studies were carried out by the agar well diffusion method against test organisms (Chung et al., 1990; Azoro, 2002). Nutrient broth (NB) plates were swabbed with 24 h old broth culture (100  $\mu$ l) of test bacteria. Using the sterile cork borer, wells (6 mm) were made into each petriplate. The compounds were dissolved in DMSO of 5 mg/ml and from this 10 and 20  $\mu$ L (50, 100  $\mu$ g/well) were added into the wells by using sterile pipettes. The standard antibiotics, Chloramphenicol, for antibacterial activity and Ketoconazole, for antifungal activity (as positive control) were simultaneously tested against the pathogens. The samples were dissolved in DMSO which showed no zone of inhibition acts as a negative control. The plates were incubated at 37 °C for 24 h for bacteria and at 28 °C for 48 h for fungi. After appropriate incubation, the diameter of zone of inhibition of each well was measured. Duplicates were maintained and the average values were calculated for eventual antibacterial activity.

**2.5.3. Minimum inhibitory concentration assay**

Broth dilution test was used to determine Minimum Inhibitory Concentration (MIC) of the above mentioned samples (Janovska et al., 2003; Bishnu et al., 2009). Freshly prepared nutrient broth was used as diluents. The 24 h old culture of the test bacteria *S. aureus*, *B. subtilis*, *P. aeruginosa*, *K. pneumoniae* and the test fungi *A. niger* and *P. chrysogenum* were diluted 100 fold in nutrient broth (100  $\mu$ l bacterial

**Table 1** The *in-vitro* antibacterial activity of compounds **3–9** by agar well diffusion method.

| Compound        | Concentration ( $\mu\text{g}/\text{Well}$ ) | Zone of inhibition (mm) |                    |                        |                      |
|-----------------|---|-------------------------|--------------------|------------------------|----------------------|
|                 |   | Gram-positive bacteria  |                    | Gram-negative bacteria |                      |
|                 |   | <i>S. aureus</i>        | <i>B. subtilis</i> | <i>P. aeruginosa</i>   | <i>K. pneumoniae</i> |
| <b>3</b>        | 50  | 18                      | 20                 | 17                     | 16                   |
|                 | 100   | 21                      | 22                 | 21                     | 19                   |
| <b>4a</b>       | 50  | —                       | —                  | —                      | —                    |
|                 | 100   | —                       | —                  | 10                     | —                    |
| <b>4b</b>       | 50  | —                       | —                  | —                      | —                    |
|                 | 100   | —                       | —                  | —                      | —                    |
| <b>4c</b>       | 50  | —                       | —                  | 9                      | —                    |
|                 | 100   | —                       | —                  | 12                     | 10                   |
| <b>5a</b>       | 50  | 8                       | —                  | 9                      | 9                    |
|                 | 100   | 10                      | 9                  | 12                     | —                    |
| <b>5b</b>       | 50  | —                       | —                  | 8                      | —                    |
|                 | 100   | —                       | —                  | 10                     | —                    |
| <b>5c</b>       | 50  | 10                      | 8                  | 12                     | 10                   |
|                 | 100   | 13                      | 11                 | 16                     | 12                   |
| <b>6a</b>       | 50  | 14                      | 13                 | 12                     | 10                   |
|                 | 100   | 17                      | 15                 | 16                     | 13                   |
| <b>6b</b>       | 50  | 9                       | 8                  | 9                      | 8                    |
|                 | 100   | 11                      | 12                 | 11                     | 10                   |
| <b>6c</b>       | 50  | 19                      | 20                 | 17                     | 15                   |
|                 | 100   | 21                      | 23                 | 19                     | 18                   |
| <b>7a</b>       | 50  | —                       | —                  | 12                     | 10                   |
|                 | 100   | —                       | —                  | 15                     | 12                   |
| <b>7b</b>       | 50  | —                       | —                  | —                      | —                    |
|                 | 100   | —                       | —                  | 10                     | 10                   |
| <b>7c</b>       | 50  | 10                      | 12                 | 14                     | 13                   |
|                 | 100   | 13                      | 14                 | 15                     | 15                   |
| <b>8a</b>       | 50  | 16                      | 15                 | 15                     | 12                   |
|                 | 100   | 18                      | 18                 | 19                     | 16                   |
| <b>8b</b>       | 50  | 13                      | 12                 | 14                     | 13                   |
|                 | 100   | 15                      | 15                 | 17                     | 16                   |
| <b>8c</b>       | 50  | 17                      | 16                 | 17                     | 15                   |
|                 | 100   | 19                      | 17                 | 20                     | 18                   |
| <b>9a</b>       | 50  | 22                      | 23                 | 20                     | 20                   |
|                 | 100   | 24                      | 28                 | 24                     | 22                   |
| <b>9b</b>       | 50  | 20                      | 19                 | 18                     | 17                   |
|                 | 100   | 23                      | 20                 | 22                     | 20                   |
| <b>9c</b>       | 50  | 25                      | 34                 | 28                     | 36                   |
|                 | 100   | 30                      | 37                 | 32                     | 38                   |
| Chloramphenicol | 50  | 33                      | 34                 | 27                     | 40                   |
|                 | 100   | 35                      | 38                 | 30                     | 42                   |
| Control (DMSO)  |   | —                       | —                  | —                      | —                    |

(—) No activity.

cultures in 10 ml NB). The stock solution of the synthesized compounds was prepared in dimethyl sulfoxide (DMSO) by dissolving 5 mg of the compound in 1 ml of DMSO. Increasing concentrations of the test samples (1.25, 2.5, 5, 10, 20, and 40  $\mu\text{l}$  of stock solution contains 6.25, 12.5, 25, 50, 100, and 200  $\mu\text{g}$  of the compounds) were added to the test tubes containing the bacterial and fungal cultures. All the tubes were incubated at 37 °C for 24 h for bacteria and at 28 °C for 48 h for fungi. The tubes were examined for visible turbidity and using NB as control. Control without test samples and with solvent was assayed simultaneously. The lowest concentration that inhibited visible growth of the tested organisms was recorded as MIC.

#### 2.5.4. Minimum bactericidal/fungicidal concentration

To determine the minimum bactericidal concentration (MBC) (NCCLS publication M7-A3; Villanova, PA, 1993) and Minimum Fungicidal Concentration (MFC) (NCCLS Document M27-P; Villanova, PA, 1992) for each set of test tubes in the MIC determination, a loopful of broth was collected from those tubes which did not show any growth and inoculated on sterile nutrient broth (for bacteria) and PDA (for fungi) by streaking. Plates inoculated with bacteria and fungi were incubated at 37 °C for 24 h and at 28 °C for 48 h, respectively. After incubation, the lowest concentration was noted as MBC (for bacteria) or MFC (for fungi) at which no visible growth was observed.






Figure 1 Antibacterial activity of 7–9.

## 2.6. Anticancer assays

### 2.6.1. Compounds

The compounds **7c**, **8c**, **9a**, **9b**, and **9c** were screened for anti-cancer activity against NCI-H1299 (Human non-small lung cancer cells; ATCC, Manassas, VA, USA), HCT-166 p53 (Human colorectal adenocarcinoma; ATCC, Manassas, VA, USA), and PC-3 (Human prostate cancer cells; ATCC, Manassas, VA, USA) cells by EZ-cytox cell viability assay kit.

### 2.6.2. Cell cultures

NCI-H1299 (Human non-small lung cancer cells; ATCC, Manassas, VA, USA), and HCT-166 p53 (Human colorectal adenocarcinoma; ATCC, Manassas, VA, USA), cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) and PC-3 (Human prostate cancer cells; ATCC, Manassas, VA, USA) cells were cultured in Roswell Park Memorial Institute Medium-1640 (RPMI-1640) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS), penicillin 100 U/ml, streptomycin 100 µg/ml, *N*-(2-hydroxyethyl)-piperazine-*N'*-2-ethanesulfonic acid (HEPES) 8 mM, and l-glutamine 2 mM. Cells were maintained at 37 °C in a humidified 5% CO<sub>2</sub> incubator.

### 2.6.3. Measurement of cancer cell viability

Cell viability and proliferation were determined with EZ-cytox cell viability assay kit (Daeil Labservice, Korea) based on the cleavage of the tetrazolium salt to water-soluble formazan by succinate-tetrazolium reductase system, which belongs to the respiratory chain of the mitochondria and is active only in the viable cells. Therefore the amount of formazan dye increased with an increase in cell viability (Kwon et al., 2010). Initially, the cells were seeded into 96-well culture plates at  $1 \times 10^4$  cells/ml and NCI-H1299 and HCT-166 p53 cells were cultured in DMEM and PC-3 cells were cultured in RPMI-

1640 media containing 10% FBS at 37 °C. When cells reached 70% confluence, the medium was replaced with DMEM or RPMI-1640 containing 10% FBS and each 100 µM of compounds for 24 h. EZ-cytox cell viability kit reagents were added to the medium, and the cells were incubated for 1 h. The index of cell viability was determined by measuring formazan production with a microplate reader at an absorbance of 450 nm. The % cell viability was calculated by the formula:

$$\% \text{ Cell viability} = \frac{\text{Mean absorbance in test wells}}{\text{Mean absorbance in control wells}} \times 100$$

As the % cell viability decreases the % inhibition increases. The % inhibition was calculated by the formula:

$$\% \text{ Inhibition} = 100 - \% \text{ cell viability.}$$

More the value of % inhibition more potent the drug is. Cells in fresh medium without any test compound were used as the control.

### 2.6.4. Statistical analysis

Experimental results are expressed as mean  $\pm$  S.E.M. One-way ANOVA followed by Dunnett's test was used for multiple comparisons. *P* values of <0.01 represent statistically significant differences.

## 3. Results and discussion

### 3.1. Chemistry

The compound ethyl sulfamylacetate (**1**) was obtained by the reaction of ethyl 2-chlorosulfonylacetate with ammonia solution (Hinman and Locatell, 1959). The compound bis(carbethoxymethylsulfonyl)amine (**2**) was prepared from

**Table 2** The *in-vitro* antifungal activity of compounds **3–9** by agar well diffusion method.


| Compound       | Concentration ( $\mu\text{g}/\text{Well}$ ) | Zone of inhibition (mm) |                       |
|----------------|---|-------------------------|-----------------------|
|                |   | <i>A. niger</i>         | <i>P. chrysogenum</i> |
| <b>3</b>       | 50  | 25                      | 24                    |
|                | 100   | 28                      | 28                    |
| <b>4a</b>      | 50  | –                       | –                     |
|                | 100   | –                       | –                     |
| <b>4b</b>      | 50  | –                       | –                     |
|                | 100   | –                       | 12                    |
| <b>4c</b>      | 50  | 10                      | 13                    |
|                | 100   | 13                      | 15                    |
| <b>5a</b>      | 50  | 14                      | 16                    |
|                | 100   | 17                      | 18                    |
| <b>5b</b>      | 50  | 12                      | 13                    |
|                | 100   | 16                      | 16                    |
| <b>5c</b>      | 50  | 18                      | 20                    |
|                | 100   | 22                      | 23                    |
| <b>6a</b>      | 50  | 22                      | 23                    |
|                | 100   | 25                      | 27                    |
| <b>6b</b>      | 50  | 18                      | 20                    |
|                | 100   | 21                      | 24                    |
| <b>6c</b>      | 50  | 25                      | 27                    |
|                | 100   | 29                      | 31                    |
| <b>7a</b>      | 50  | –                       | –                     |
|                | 100   | –                       | –                     |
| <b>7b</b>      | 50  | –                       | –                     |
|                | 100   | –                       | –                     |
| <b>7c</b>      | 50  | 10                      | 14                    |
|                | 100   | 12                      | 17                    |
| <b>8a</b>      | 50  | 20                      | 23                    |
|                | 100   | 24                      | 26                    |
| <b>8b</b>      | 50  | 19                      | 21                    |
|                | 100   | 22                      | 24                    |
| <b>8c</b>      | 50  | 24                      | 24                    |
|                | 100   | 26                      | 28                    |
| <b>9a</b>      | 50  | 27                      | 29                    |
|                | 100   | 30                      | 34                    |
| <b>9b</b>      | 50  | 22                      | 24                    |
|                | 100   | 25                      | 26                    |
| <b>9c</b>      | 50  | 32                      | 36                    |
|                | 100   | 36                      | 39                    |
| Ketoconazole   | 50  | 33                      | 36                    |
|                | 100   | 36                      | 38                    |
| Control (DMSO) |   | –                       | –                     |


(–) No activity.

ethyl 2-chlorosulfonylacetate and **1** in the presence of catalytic amounts of 4-dimethylaminopyridine (DMAP) and triethylamine (Scheme 1). The  $^1\text{H}$  NMR spectrum of **2** displayed a triplet and a quartet at  $\delta$  1.36 and 4.20 for ethoxy protons, a singlet at 4.42 for methylene protons and a broad singlet at 8.01 ppm for NH. The compound **2** on hydrolysis gave bis(carboxymethylsulfonyl)amine (**3**). The absence of signals due to the ethoxy group in the  $^1\text{H}$  NMR spectrum of **3** indicated that hydrolysis occurred. Besides, a broad singlet was observed at  $\delta$  10.43 ppm due to hydroxy protons in addition to signals of the methylene and NH protons. The signals due to highly acidic protons in **2** and **3** disappeared on deuteration. The compounds 4-aryloxazol-2-amine (**4**) and 4-arylthiazol-2-amine (**5**) were prepared by adopting the literature precedent from phenacyl bromide and urea/thiourea (Potewar et al., 2008). The compound 4-aryl-1*H*-imidazole-2-amine (**6**) was obtained by the

reaction of phenacyl bromide with acetyl guanidine followed by hydrolysis under acidic conditions (Little and Webber, 1994). The coupling reaction of **3** with **4** in the presence of DCC and DMAP resulted in bis(*N*-(4-aryloxazol-2-yl)aminocarbonylmethylsulfonyl)amine (**7**). Similarly, the compounds bis(*N*-(4-arylthiazol-2-yl)aminocarbonylmethylsulfonyl)amine (**8**) and bis(*N*-(4-aryl-1*H*-imidazol-2-yl)aminocarbonylmethylsulfonyl)amine (**9**) were synthesized by the reaction of **3** with **5** and **6** (Scheme 1). The  $^1\text{H}$  NMR spectra of **7a**, **8a** and **9a** exhibited a singlet at  $\delta$  4.52, 4.45 and 4.40 for methylene protons, two broad singlets at  $\delta$  8.03, 7.94, 8.04 and 8.46, 8.42, and 8.38 for  $\text{SO}_2\text{NH}$  and  $\text{CONH}$ , respectively. However, a singlet due to  $\text{C}_5\text{-H}$  appeared in a more downfield region, merged with aromatic protons at 7.53, 7.50 and 7.45 ppm. The structures of all the compounds were further ascertained by IR,  $^{13}\text{C}$  NMR spectra and microanalyses.








**Figure 3** Effects of amido sulfonamido methane linked bis heterocycles on cancer cell lines. Cells were seeded in 96-well culture plates at  $1 \times 10^4$  cells/ml NCI-H1299 and HCT-166 p53 cells were cultured in DMEM and PC-3 cells were cultured in RPMI-1640 media containing 10% FBS at 37 °C. When cells reached 70% confluence, the medium was replaced with DMEM or RPMI-1640 containing 10% FBS and 100 μM of amido sulfonamido methane linked bis heterocycles (7c, 8c, 9a, 9b and 9c) for 23 h. Values represent means  $\pm$  S.E.M. from three different assays. (A) NCI-H1299, (B) HCT-166 p53, and (C) PC-3 cancer cell line. \*\* $p < 0.01$  compared with control.

**Table 4** Anticancer activity of 7c, 8c, 9a, 9b and 9c on NCI-H1299, HCT-166 p53 and PC-3 cell lines at 100 μM concentration. Cell viability in %.

| Compound | NCI-H1299                  |            |  | HCT-166 p53                |            |  | PC-3                       |            |  |
|----------|----------------------------|------------|--|----------------------------|------------|--|----------------------------|------------|--|
|          | % Viability (% inhibition) | SD         |  | % Viability (% inhibition) | SD         |  | % Viability (% inhibition) | SD         |  |
| Control  | 100.00 (0)                 | $\pm 1.76$ |  | 100.00 (0)                 | $\pm 2.01$ |  | 100.00 (0)                 | $\pm 1.34$ |  |
| 7c       | 70.93 (29.07)              | $\pm 4.08$ |  | 101.50 (−1.5)              | $\pm 2.43$ |  | 90.68 (9.32)               | $\pm 4.76$ |  |
| 8c       | 85.68 (14.32)              | $\pm 3.40$ |  | 100.80 (−0.8)              | $\pm 3.10$ |  | 95.21 (4.79)               | $\pm 1.39$ |  |
| 9a       | 97.45 (2.55)               | $\pm 2.67$ |  | 102.52 (−2.52)             | $\pm 2.07$ |  | 100.53 (−0.53)             | $\pm 4.29$ |  |
| 9b       | 86.24 (13.76)              | $\pm 2.47$ |  | 96.69 (3.31)               | $\pm 5.64$ |  | 90.95 (9.05)               | $\pm 1.15$ |  |
| 9c       | 21.40 (78.60)              | $\pm 2.25$ |  | 41.38 (58.62)              | $\pm 1.78$ |  | 32.09 (67.91)              | $\pm 4.23$ |  |

**Table 5** Anticancer activity of 9c on NCI-H1299, HCT-166 p53 and PC-3 cell lines at 0, 10, 50, and 100 μM concentrations. Cell viability in %.

| Compound 9c (μM) | NCI-H1299                  |            |  | HCT-166 p53                |            |  | PC-3                       |            |  |
|------------------|----------------------------|------------|--|----------------------------|------------|--|----------------------------|------------|--|
|                  | % Viability (% inhibition) | SD         |  | % Viability (% inhibition) | SD         |  | % Viability (% inhibition) | SD         |  |
| 0                | 100.00 (0)                 | $\pm 3.10$ |  | 100.00 (0)                 | $\pm 3.10$ |  | 100.00 (0)                 | $\pm 3.10$ |  |
| 10               | 98.26 (1.74)               | $\pm 3.08$ |  | 102.67 (−2.67)             | $\pm 8.11$ |  | 54.90 (45.10)              | $\pm 3.00$ |  |
| 50               | 19.99 (80.01)              | $\pm 8.33$ |  | 89.12 (10.88)              | $\pm 1.43$ |  | 39.38 (60.62)              | $\pm 1.28$ |  |
| 100              | 19.28 (80.72)              | $\pm 3.60$ |  | 44.00 (56.00)              | $\pm 0.34$ |  | 36.61 (63.39)              | $\pm 3.40$ |  |



**Figure 4** The effect of compound **9c** on NCI-H1299, HCT-166 p53 and PC-3 cancer cell lines: precultured, treated with compound **9c** (0–100  $\mu$ M) for 23 h, EZ-cytox cell viability kit reagents were added to the medium and the cells were incubated for 1 h. The optical density was determined at 450 nm using a microplate reader. Values represent means  $\pm$  S.E.M. from three different assays. (A) NCI-H1299, (B) HCT166 p53, and (C) PC-3 cancer cell line. \*\* $p < 0.01$  compared with control.

(HCT-166 p53) and prostate (PC-3) cancer cell lines by EZ-cytox cell viability assay kit. To determine the anticancer activity of bis heterocycles **7–9**, the cancer cells were treated at concentrations from 100  $\mu$ M for 24 h and measured the cell viability using the EZ-cytox cell viability kit. As shown in Fig. 3, the evidence of the anticancer effect of compound **9c** on NCI-H1299, HCT-166 p53 and PC-3 cancer cells can be seen. The inhibition percentage of compound **9c** was 78.60 (NCI-H1299), 58.62 (HCT-166 p53) and 67.91 (PC-3) at 100  $\mu$ M, respectively (Table 4 and Fig. 3). With compound **9c** (0–100  $\mu$ M) stimulation for 24 h, cancer cells also decreased in a dose-dependent manner (Table 5 and Fig. 4). This result suggests that the compound **9c** pre-treatment was clearly shown to modulate the anticancer activity.

#### 4. Conclusion

- A new class of amido-sulfonamido methane linked bis heterocycles-bisoxazoles (**7**), bisthiazoles (**8**) and bisimidazoles (**9**) were prepared from bis(carboxymethyl-sulfonyl)amine and amino-oxazoles (**4**), thiazoles (**5**) and imidazoles (**6**).
- Bis heterocycles (**7–9**) were found more active than the respective mono heterocycles (**4–6**).
- The compounds having oxazole unit **4** and **7** were found inactive against both bacteria and fungi.
- Compounds having chloro substituent showed good antimicrobial activity.
- The chloro substituted bisimidazole **9c** exhibited excellent antibacterial activity against *B. subtilis*, *P. aeruginosa* and antifungal activity against *A. niger*, and *P. chrysogenum*.

- The compound **9c** was the most potent compound on cancer cells which may potentiate cancer therapy regimens now in the development of lung, colon and prostate cancer cell lines.

#### Acknowledgements

One of the authors V. Padmavathi is grateful to DST, New Delhi, for financial assistance under a major research project.

#### References

- Ali, A., Reddy, G.S.K.K., Cao, H., Anjum, S.G., Nalam, M.N.L., Schiffer, C.A., Rana, T.M., 2006. *J. Med. Chem.* 49, 7342–7356.
- Azoro, C., 2002. *World J. Biotechnol.* 3, 347–357.
- Bishnu, J., Sunil, L., Anuja, S., 2009. *J. Sci. Eng. Technol.* 5, 143–150.
- Breccia, A., Cavalleri, B., Adams, G.E., 1986. *Chemistry, Pharmacology and Clinical Applications*. Plenum Press, VCH, Florida.
- Chung, K.T., Thomasson, W.R., Wu-Yuan, C.D., 1990. *J. Appl. Bacteriol.* 69, 498–503.
- Degnan, B.M., Hawkins, C.J., Lavin, M.F., McCaffrey, E.J., Parry, D.L., Watters, D.J., 1989. *J. Med. Chem.* 32, 1354–1359.
- Hinman, R.L., Locatell Jr., L., 1959. *J. Am. Chem. Soc.* 5, 5655–5658.
- Janovska, D., Kubikova, K., Kokoska, L., 2003. *J. Food Sci.* 21, 107–110.
- Kwon, H.K., Hwang, J.S., So, J.S., Lee, C.G., Sahoo, A., Ryu, J.H., Jeon, W.K., Ko, B.S., Im, C.R., Lee, S.H., Park, Z.Y., Im, S.H., 2010. *BMC Cancer* 10, 392.
- Little, T.L., Webber, S.E., 1994. *J. Org. Chem.* 59, 7299–7305.
- McCarroll, A.J., Bradshaw, T.D., Westwell, A.D., Matthews, C.S., Stevens, M.F.G., 2007. *J. Med. Chem.* 50, 1707–1710.
- Middlemiss, D., Watson, S.P., 1994. *Tetrahedron* 50, 13049–13080.

- Miller, J.P., Stoodley, R.J., 2011. *J. Saudi Chem. Soc.* 15, 275–281.
- National committee for clinical laboratory standards, reference method for broth dilution antifungal susceptibility testing of yeasts, proposed standard, 1992. NCCLS Document M27-P. Villanova, PA.
- National committee for clinical laboratory standards methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3d edition; approved standard, NCCLS publication M7-A3; Villanova, PA, 1993.
- Perez, L.J., Faulkner, D.J., 2003. *J. Nat. Prod.* 66, 247–250.
- Pihko, P.M., Koskinen, A.M.P., 1998. *J. Org. Chem.* 63, 92–98.
- Potewar, T.M., Ingale, S.A., Srinivasan, K.V., 2008. *Tetrahedron* 64, 5019–5022.
- Rudi, A., Chill, L., Akin, M., Kashman, Y., 2003. *J. Nat. Prod.* 66, 575–577.
- Tan, L.T., Sitachitta, N., Gerwick, W.H., 2003. *J. Nat. Prod.* 66, 764–771.
- Wilkinson, B.L., Bomaghi, L.F., Houston, T.A., Innocenti, A., Vullo, D., Supuran, C.T., Poulsen, S.A., 2007. *J. Med. Chem.* 50, 1651–1657.
- Yokokawa, F., Sameshima, H., Shioiri, T., 2001. *Tetrahedron Lett.* 42, 4171–4174.
- You, S.-L., Kelly, J.W., 2005a. *Tetrahedron* 61, 241–249.
- You, S.-L., Kelly, J.W., 2005b. *Tetrahedron Lett.* 46, 2567–2570.